We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PSA Levels Detected by Microfluidics Cartridge and Reader

By LabMedica International staff writers
Posted on 01 Apr 2010
Prostate specific antigen (PSA) levels in prostate cancer patients can be detected by a microfluidics cartridge and reader in 15 minutes. More...
The disposable cartridge, about the size of a credit card, requires only a small drop of blood; the reader is comparable in size to a toaster.

The surface of the cartridge is covered in narrow channels, which serve as both storage for the chemicals needed for the assay and as tiny test tubes in which to carry out the reaction. Each reagent is lined up sequentially in one long channel and separated by small air bubbles. The cartridge is inserted into the reader, a vacuum pulls the blood through one channel, and reagents are delivered in appropriate sequence.

The reader uses a light-emitting diode (LED) and photodiode to detect the amount of silver, a product of the reaction, on the cartridge. The more silver, the less light passes through the chip and the higher the PSA level.

Microfluidics, which allows for the manipulation of fluids on a chip at microscopic quantities, has been limited largely to research because of its complexity and expense.

The microfluidics technology for determining patients' PSA levels was developed by Claros Diagnostics (Woburn, MA, USA). If approved by the U.S. Food and Drug Administration, the device will be one of the first examples of microfluidics-based diagnostics tests that can be performed in the hospital or doctor's office.

Scientists at Claros developed low-cost injection molding technologies that permit the hard-plastic cartridges to be made very quickly, in about 15 seconds, and for about US$0.10 apiece. The approach avoids the pumps that are used to move chemicals in other microfluidics chips, enabling a simple and robust design with no moving parts.

Clinical trials of the new device are underway and if successful the company plans to launch the device in Europe later this year and in the United States in 2011. Similar technology could be used to create screening panels for women's health or cardiac health.

Related Links:

Claros Diagnostics


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Fusun Can (at left) is developing a test for detecting both resistance and virulence in Klebsiella pneumoniae (Photo courtesy of Koç University)

Rapid Diagnostic Breakthrough Simultaneously Detects Resistance and Virulence in Klebsiella Pneumoniae

Antibiotic resistance is a steadily escalating threat to global healthcare, making common infections harder to treat and increasing the risk of severe complications. One of the most concerning pathogens... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.